ENABLE Adherence
Discover ENABLE: Who we are
About us
ENABLE Adherence
NOVEL TECHNOLOGICAL ADVANCES
Discover more
ENABLE Adherence
NEWS
Discover more
ENABLE Adherence
HOW TO JOIN US?
Contact us
Previous
Next

Action on medication adherence

The COST Action “European Network to Advance Best practices & technoLogy on medication adherencE” (ENABLE) CA19132 aims to create a multidisciplinary network of relevant stakeholders that work collaboratively towards economically viable implementation of medication adherence enhancing technologies across different European healthcare systems.

Our motivation, or better WHY?

Due to an ageing society, there is a steady increase in chronic diseases and multi-morbidity in Europe. This requires a multidisciplinary response, which often involves lifestyle changes combined with lifetime medication use.

Technological advances (e.g. smart pillboxes, digital inhalers, tracking devices, e-injection pens, e-Health, big data), have significant potential to support healthcare professionals and empower patients in detecting and managing non-adherence.

Knowledge

What is already known about medication adherence

Focus

What is this project focused on delivering to it's public

Challenge

What is this projects approach to the challenges up ahead

Our Goals

The main aim and objective of the Action is to create a multidisciplinary network of relevant stakeholders that work collaboratively towards economically viable implementation of medication adherence enhancing technologies across different European healthcare systems, through:

The specific objectives of this Action are:

Impact

anshu-a-oNvTBKUd83o-unsplash

Scientific and societal impact

Several important scientific and technological impacts are anticipated. These include:

In the short term impact several important scientific and technological impacts are anticipated due to increased multidisciplinary and private-public collaboration on medication adherence.

Economic impact of medication adherence

ENABLE will tackle a highly relevant issue with substantial cross-sectorial impact. Systematic reviews indicate a wide-ranging negative impact of non-adherence, and reveal consistent associations of nonadherence to worse clinical (i.e. 200,000 deaths) as well as economic outcomes (i.e. €80-125 billion) across the full spectrum of chronic diseases.

economic-impact
leon-Oalh2MojUuk-unsplash

Added value of networking

Information generated and disseminated through the ENABLE Action will stimulate SMEs and investors even more to develop medical technology (technological impact), being guided by easily accessible local medication adherence expertise centers and a pan-European web platform that help them to reach their end-users and give them a better and more transparent idea of their potential European market share.

Complementarity with other research programmes

As compared to existing efforts outlined above, the ENABLE COST Action will have a unique and specific focus that goes beyond the objectives of the existing efforts. It will be disease and discipline overarching, is multidisciplinary (providers, patients, policy makers), incorporates the latest state-of- the-art adherence enhancing technology through SME involvement and has a strong focus on sustainable, cost-effective implementation across Europe.

isaac-quesada-Loahp7cXIf4-unsplash

Let's Connect

Don't miss new updates on your email